Scholar Rock (NASDAQ:SRRK) Insider Jing Marantz Sells 4,157 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Jing Marantz sold 4,157 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the completion of the transaction, the insider directly owned 126,012 shares in the company, valued at approximately $5,863,338.36. This represents a 3.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Scholar Rock Stock Performance

NASDAQ:SRRK traded up $0.19 during mid-day trading on Friday, reaching $47.89. 808,795 shares of the company’s stock were exchanged, compared to its average volume of 998,473. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30. Scholar Rock Holding Corporation has a one year low of $22.71 and a one year high of $49.82. The business’s fifty day simple moving average is $45.14 and its two-hundred day simple moving average is $38.30. The firm has a market capitalization of $4.89 billion, a PE ratio of -15.30 and a beta of 0.67.

Analyst Ratings Changes

SRRK has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price target on Scholar Rock from $46.00 to $47.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. BMO Capital Markets reiterated an “outperform” rating and issued a $50.00 target price on shares of Scholar Rock in a research report on Friday, November 14th. Barclays boosted their price target on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Finally, UBS Group initiated coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They set a “buy” rating and a $60.00 target price on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $51.14.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently modified their holdings of the company. Moody Aldrich Partners LLC increased its stake in Scholar Rock by 53.5% in the 3rd quarter. Moody Aldrich Partners LLC now owns 101,742 shares of the company’s stock worth $3,789,000 after acquiring an additional 35,481 shares during the last quarter. Norges Bank purchased a new stake in Scholar Rock in the second quarter valued at approximately $41,628,000. Voya Investment Management LLC grew its stake in Scholar Rock by 18.1% in the 3rd quarter. Voya Investment Management LLC now owns 443,155 shares of the company’s stock worth $16,503,000 after buying an additional 67,839 shares in the last quarter. Ensign Peak Advisors Inc grew its stake in Scholar Rock by 78.8% in the 2nd quarter. Ensign Peak Advisors Inc now owns 600,639 shares of the company’s stock worth $21,275,000 after buying an additional 264,693 shares in the last quarter. Finally, Nan Fung Trinity HK Ltd. bought a new position in shares of Scholar Rock in the 3rd quarter worth $1,402,000. 91.08% of the stock is currently owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).